Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand

by Nitichen Kittiratchakool, Disorn Kulpokin, Chonticha Chanjam, Soamarat Vilaiyuk, Sirirat Charuvanij, Gun Phongsamart, Parichat Khaosut, Manasita Tanya, Ratanavadee Nanagara, Sira Nantapaisarn, Pattara Leelahavarong
Published 2020-09-01